ArticleImmunity2021
Functional impairment of HIV-specific CD8
Open access · greenAbstract read
In one paragraph
Article in Immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 54 citations in OpenAlex.
- Trial
- Trial
- Natural killers blast HIV reservoir landscape.Nature immunology · 2026Article
- In vivo effect of anti-PD-1 on HIV-specific CD8+T-cells in men with HIV.Nature communications · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- The HIV reservoir landscape in elite controllers.Current opinion in HIV and AIDS · 2026Review
- Recapitulating the qualities of HIV-specific CD8 + T cells from spontaneous controllers.Current opinion in HIV and AIDS · 2026Review
- Single-cell profiling reveals immunometabolic remodeling with T-cell dysfunction in HIV-1 infected people.Infectious diseases & immunity · 2026Article
- Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control.Nature immunology · 2026Article
- Persistent viral control status is associated with enhanced innate immune responses in people with HIV-1.iScience · 2026Article
- Review
- Duration of Initial Viremia Modulates Functional Properties of HIV-specific T Cell Receptors.Research square · 2026Article
- Duration of Initial Viremia Modulates Functional Properties of HIV-specific T Cell Receptors.bioRxiv : the preprint server for biology · 2026Article
- CD8Nature · 2026Article
- Transcription factor BACH2 shapes tissue-resident memory T cell programs to promote HIV-1 persistence.Immunity · 2025Article
- CD8medRxiv : the preprint server for health sciences · 2025Article
- Distinct viral reservoirs and immune signatures in individuals on long-term antiretroviral therapy with perinatally acquired HIV-1.Cell reports. Medicine · 2025Article
- Immune signatures and biomarkers of viral control in early-treated children with HIV: insights informing intervention.Current opinion in HIV and AIDS · 2025Review
- Persistent elite controllers as the key model to identify permanent HIV remission.Current opinion in HIV and AIDS · 2025Review
- Circulating immune landscape and immune signatures in spontaneous HIV controllers.Frontiers in immunology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 2 countries.
David R CollinsRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Jonathan M UrbachRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Zachary J RacenetRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Umar ArshadRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Karen A PowerRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Ruchi M NewmanRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Geetha H MylvaganamRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Ngoc L LyRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Xiaodong LianRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
Anna RullJoan XXIII University Hospital, Pere Virgili Institute (IISPV), Rovira i Virgili University, Tarragona, Spain.
Yelizaveta RassadkinaRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
Adrienne G YanezRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Michael J PelusoDivision of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, CA, USA.
Steven G DeeksDivision of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, CA, USA.
Francesc VidalJoan XXIII University Hospital, Pere Virgili Institute (IISPV), Rovira i Virgili University, Tarragona, Spain.
Mathias LichterfeldRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
Xu G YuRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
Gaurav D GaihaRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
Todd M AllenRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Bruce D WalkerRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA; Institute for Medical Engineering and Sciences and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. Electronic address: bwalker@mgh.harvard.edu.
Ragon Institute of MGH, MIT and Harvard · USBrigham and Women's Hospital · USHoward Hughes Medical Institute · USInstitut de Recerca Biomèdica Catalunya Sud · ESUniversity of California, San Francisco · US
Funding
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4MThe impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4MVirology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER W HUNT · 1988 to 2026
$93.6MViral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVENSON, MARIO · 2011 to 2015
$29.5MDelaney AIDS Research Enterprise to Cure HIVUM1AI126611 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT, PICKER, LOUIS J. · 2016 to 2020
$27.9MTraining in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4MElite controllers as a model for a cure of HIV-1 infectionR37AI155171 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Xu Yu · 2020 to 2026
$5.2MSelection and Evolution of HIV-1 reservoir cells in blood and tissuesR01AI152979 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ESTES, JACOB D, LICHTERFELD, MATHIAS · 2020 to 2025
$3.8MA systems biology approach to fingerprint HIV immune defense in Elite ControllersR01HL134539 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2016 to 2019
$3.3MProteomics and phosphoproteomics analysis in HIV-1 infectionR01AI130005 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LICHTERFELD, MATHIAS · 2017 to 2021
$2.9MExploiting Highly Networked CTL Epitopes to Achieve a Functional HIV CureDP2AI154421 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GAIHA, GAURAV DAS · 2020 to 2024
$2.7MMolecular networks of HIV-specific CD4 T cell help to B cellsR01AI118544 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2015 to 2019
$2.2MNHLBI NIH HHS R01 HL134539NIAID NIH HHS DP2 AI154421NIAID NIH HHS DP2 AI184606NIAID NIH HHS K23 AI157875NIAID NIH HHS K24 AI155233NIAID NIH HHS L30 AI126472NIAID NIH HHS L30 AI147159NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI118544NIAID NIH HHS R01 AI130005NIAID NIH HHS R01 AI149704NIAID NIH HHS R01 AI152979NIAID NIH HHS R24 AI067039NIAID NIH HHS R37 AI155171NIAID NIH HHS T32 AI060530NIAID NIH HHS U19 AI096109NIAID NIH HHS UM1 AI126611
Abstract
Spontaneous control of HIV infection has been repeatedly linked to antiviral CD8
Indexed as
AdultCD8-Positive T-LymphocytesFemaleHIV InfectionsHumansMaleMiddle AgedRecurrenceViremiaCD8(+) T cell dysfunctionHIV controlhuman immunology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.